{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:32Z","timestamp":1792783352941,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Biotechnology","id":[{"id":"https:\/\/ror.org\/03tjsyq23","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Council of Scientific and Industrial Research","id":[{"id":"https:\/\/ror.org\/021wm7p51","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01831-1","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:53Z","timestamp":1790680853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the Epigenetic\u2013Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions"],"prefix":"10.1007","volume":"28","author":[{"given":"Devangi","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7894-8297","authenticated-orcid":false,"given":"Subhasree","family":"Roy Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1831_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1612702","author":"M Du","year":"2019","unstructured":"Du M, Chen W, Liu K, Wang L, Hu Y, Mao Y, et al. The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the Global Burden of Disease 2019 study and projections to 2030. Journal of Oncology. 2022;1612702. https:\/\/doi.org\/10.1155\/2022\/1612702","journal-title":"J Oncol"},{"issue":"4","key":"1831_CR2","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49(4):e324\u2013e324. https:\/\/doi.org\/10.1038\/emm.2017.11.","journal-title":"Exp Mol Med"},{"key":"1831_CR3","doi-asserted-by":"publisher","unstructured":"Ochi Y, Liew-Littorin M, Nannya Y, Bengtzen S, Piauger B, Deneberg S, et al. Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia. Nature. 2026;1\u201311. https:\/\/doi.org\/10.1038\/s41586-026-10703-4.","DOI":"10.1038\/s41586-026-10703-4"},{"key":"1831_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/J.STEM.2016.10.019","volume":"19","author":"M Farlik","year":"2016","unstructured":"Farlik M, Halbritter F, M\u00fcller F, Choudry FA, Ebert P, Klughammer J, et al. DNA methylation dynamics of human hematopoietic stem cell differentiation. Cell Stem Cell. 2016;19:808\u201322. https:\/\/doi.org\/10.1016\/J.STEM.2016.10.019.","journal-title":"Cell Stem Cell"},{"key":"1831_CR5","doi-asserted-by":"publisher","unstructured":"Wagner VP, Martins MD, Castilho RM. Histones acetylation and cancer stem cells (CSCs). In: Methods in Molecular Biology, vol. 1692. Humana Press Inc.; 2018. p. 179\u201393. . https:\/\/doi.org\/10.1007\/978-1-4939-7401-6_16","DOI":"10.1007\/978-1-4939-7401-6_16"},{"key":"1831_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-015-0151-8","author":"C Zhang","year":"2015","unstructured":"Zhang C, Zhong JF, Stucky A, Chen XL, Press MF, Zhang X. Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics. 2015;7:117. https:\/\/doi.org\/10.1186\/s13148-015-0151-8.","journal-title":"Clin Epigenetics"},{"key":"1831_CR7","doi-asserted-by":"publisher","first-page":"443766","DOI":"10.3389\/FONC.2019.00432","volume":"9","author":"A Dhall","year":"2019","unstructured":"Dhall A, Zee BM, Yan F, Blanco MA. Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia. Front Oncol. 2019;9:443766. https:\/\/doi.org\/10.3389\/FONC.2019.00432","journal-title":"Front Oncol [Internet] Front Media S A"},{"key":"1831_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1182\/BLOOD-2010-07-294827","volume":"118","author":"J Zhou","year":"2011","unstructured":"Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011;118:2830\u20139. https:\/\/doi.org\/10.1182\/BLOOD-2010-07-294827.","journal-title":"Blood"},{"key":"1831_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/BLOOD-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346\u201357. https:\/\/doi.org\/10.1182\/BLOOD-2014-06-581082.","journal-title":"Blood"},{"key":"1831_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/NCHEMBIO.1084","volume":"8","author":"SK Knutson","year":"2012","unstructured":"Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8:890\u20136. https:\/\/doi.org\/10.1038\/NCHEMBIO.1084.","journal-title":"Nat Chem Biol"},{"key":"1831_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/NATURE11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108\u201312. https:\/\/doi.org\/10.1038\/NATURE11606.","journal-title":"Nature"},{"key":"1831_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/NCHEMBIO.1331","volume":"9","author":"W Kim","year":"2013","unstructured":"Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9:643\u201350. https:\/\/doi.org\/10.1038\/NCHEMBIO.1331.","journal-title":"Nat Chem Biol"},{"key":"1831_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1120911","volume":"14","author":"B Noce","year":"2023","unstructured":"Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911. https:\/\/doi.org\/10.3389\/fphar.2023.1120911.","journal-title":"Front Pharmacol"},{"key":"1831_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/J.CCR.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473\u201387. https:\/\/doi.org\/10.1016\/J.CCR.2012.03.014.","journal-title":"Cancer Cell"},{"key":"1831_CR15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/LEU.2014.119","volume":"28","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014;28:2155\u20132164. https:\/\/doi.org\/10.1038\/LEU.2014.119","journal-title":"Leukemia"},{"key":"1831_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/BLOOD.2025029712","volume":"147","author":"V Fetsch","year":"2026","unstructured":"Fetsch V, Schw\u00f6bel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, et al. Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood. 2026;147:584\u2013601. https:\/\/doi.org\/10.1182\/BLOOD.2025029712.","journal-title":"Blood"},{"key":"1831_CR17","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/1535-7163.MCT-08-0411","volume":"7","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7:2998\u20133005. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0411.","journal-title":"Mol Cancer Ther"},{"key":"1831_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/LEU.2008.397","volume":"23","author":"C Flotho","year":"2009","unstructured":"Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23:1019\u201328. https:\/\/doi.org\/10.1038\/LEU.2008.397.","journal-title":"Leukemia"},{"key":"1831_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMOA1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398. . https:\/\/doi.org\/10.1056\/NEJMOA1716984","journal-title":"N Engl J Med"},{"key":"1831_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/LEU.2015.346","volume":"30","author":"E Chang","year":"2016","unstructured":"Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3\/ITD acute myeloid leukemia cells. Leukemia. 2016;30:1025\u201332. https:\/\/doi.org\/10.1038\/LEU.2015.346.","journal-title":"Leukemia"},{"key":"1831_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/IJC.25660","volume":"129","author":"S Zhang","year":"2011","unstructured":"Zhang S, Suvannasankha A, Crean CD, White VL, Chen CS, Farag SS. The novel histone deacetylase inhibitor, AR-42, inhibits gp130\/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. Int J Cancer. 2011;129:204\u201313. https:\/\/doi.org\/10.1002\/IJC.25660.","journal-title":"Int J Cancer"},{"key":"1831_CR22","doi-asserted-by":"publisher","first-page":"31134","DOI":"10.18632\/ONCOTARGET.5290","volume":"6","author":"A Canella","year":"2015","unstructured":"Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, et al. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 2015;6:31134\u201350. https:\/\/doi.org\/10.18632\/ONCOTARGET.5290.","journal-title":"Oncotarget"},{"key":"1831_CR23","doi-asserted-by":"publisher","unstructured":"Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Translational Oncology. 2022;16:101312. https:\/\/doi.org\/10.1016\/J.TRANON.2021.101312","DOI":"10.1016\/J.TRANON.2021.101312"},{"key":"1831_CR24","doi-asserted-by":"publisher","unstructured":"K\u00fchn MWM, Pemmaraju N, Heidel FH. The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms. Leukemia 2025;39:8. https:\/\/doi.org\/10.1038\/s41375-025-02639-x","DOI":"10.1038\/s41375-025-02639-x"},{"key":"1831_CR25","doi-asserted-by":"publisher","unstructured":"Akpa CA, Kleo K, Lenze D, Oker E, Dimitrova L, Hummel M. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. PLoS One. 2019;14(8): e0220681. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0220681","DOI":"10.1371\/JOURNAL.PONE.0220681"},{"key":"1831_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9071639","author":"J Rinke","year":"2020","unstructured":"Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. EZH2 in myeloid malignancies. Cells. 2020;9(7):1639. https:\/\/doi.org\/10.3390\/CELLS9071639","journal-title":"Cells"},{"key":"1831_CR27","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1111\/CAS.15122","volume":"112","author":"H Yuan","year":"2021","unstructured":"Yuan H, Nishikori M, Otsuka Y, Arima H, Kitawaki T, Takaori-Kondo A. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17\/TARC in B-cell lymphoma and enhances T\u2010cell recruitment. Cancer Sci. 2021;112:4604. https:\/\/doi.org\/10.1111\/CAS.15122.","journal-title":"Cancer Sci"},{"key":"1831_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2023.1120911","author":"B Noce","year":"2023","unstructured":"Noce B, Di Bello E, Fioravanti R, Mai A. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials. Front Pharmacol. 2023;14:1120911. https:\/\/doi.org\/10.3389\/FPHAR.2023.1120911","journal-title":"Front Pharmacol [Internet] Front Media SA"},{"key":"1831_CR29","doi-asserted-by":"publisher","first-page":"113934","DOI":"10.1016\/J.BIOPHA.2022.113934","volume":"157","author":"C Agboyibor","year":"2023","unstructured":"Agboyibor C, Dong J, Effah CY, Drokow EK, Ampomah-Wireko M, Pervaiz W, et al. Epigenetic compounds targeting pharmacological target lysine specific demethylase 1 and its impact on immunotherapy, chemotherapy and radiotherapy for treatment of tumor recurrence and resistance. Biomedicine & Pharmacotherapy. 2023;157:113934. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113934","journal-title":"Biomed Pharmacotherapy Elsevier Masson"},{"key":"1831_CR30","doi-asserted-by":"publisher","unstructured":"Kanouni T, Severin C, Cho RW, Yuen NYY, Xu J, Shi L et al. Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020;63:14522\u20139. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.0C00978","DOI":"10.1021\/ACS.JMEDCHEM.0C00978"},{"key":"1831_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/14728214.2019.1694001","volume":"24","author":"MR Pandey","year":"2019","unstructured":"Pandey MR, Wang ES. What potential is there for LSD1 inhibitors to reach approval for AML? Expert Opinion on Emerging Drugs. 2019;24(4):205\u2013212. https:\/\/doi.org\/10.1080\/14728214.2019.1694001","journal-title":"Expert Opin Emerg Drugs"},{"key":"1831_CR32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Dos Santos HG, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 2021;27:1893. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4054.","journal-title":"Clin Cancer Res"},{"key":"1831_CR33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/BLOOD.2021012806","volume":"139","author":"EB Heikamp","year":"2022","unstructured":"Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139:894. https:\/\/doi.org\/10.1182\/BLOOD.2021012806.","journal-title":"Blood"},{"key":"1831_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/S41408-021-00603-3","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, et al. Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022;12(5). https:\/\/doi.org\/10.1038\/S41408-021-00603-3","journal-title":"Blood Cancer J"},{"key":"1831_CR35","doi-asserted-by":"publisher","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920-924. https:\/\/doi.org\/10.1038\/s41586-023-05812-3","DOI":"10.1038\/s41586-023-05812-3"},{"key":"1831_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/BLOOD-2023-182337","volume":"142","author":"GC Issa","year":"2023","unstructured":"Issa GC, Cuglievan B, DiNardo CD, Short NJ, McCall D, Gibson A, et al. Early results of the phase I\/II study investigating the all-oral combination of the menin inhibitor Revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE). Blood. 2023;142:58\u201358. https:\/\/doi.org\/10.1182\/BLOOD-2023-182337.","journal-title":"Blood"},{"key":"1831_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/S40487-024-00262-X","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X. Small molecule menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024;12:57-72. https:\/\/doi.org\/10.1007\/S40487-024-00262-X.","journal-title":"Oncol Ther"},{"key":"1831_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/HEM.V19.5.2022513","author":"CM McMahon","year":"2022","unstructured":"McMahon CM. Menin inhibitors: a promising class of targeted therapies for KMT2A-rearranged and NPM1-mutated acute leukemias. Hematologist. 2022;19:5. https:\/\/doi.org\/10.1182\/HEM.V19.5.2022513","journal-title":"Hematologist"},{"key":"1831_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/15592294.2019.1699991","volume":"15","author":"F Sarno","year":"2020","unstructured":"Sarno F, Nebbioso A, Altucci L. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics. 2020;15:439\u201353. https:\/\/doi.org\/10.1080\/15592294.2019.1699991.","journal-title":"Epigenetics"},{"key":"1831_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-022-01251-1","volume":"15","author":"Y Yi","year":"2022","unstructured":"Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 2022;15:35. https:\/\/doi.org\/10.1186\/S13045-022-01251-1.","journal-title":"J Hematol Oncol"},{"key":"1831_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01251-1","volume":"15","author":"Y Yi","year":"2022","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small- molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65. https:\/\/doi.org\/10.1016\/j.ccr.2011.06.009.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1831_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3390\/IJMS20051029","volume":"20","author":"A Skucha","year":"2019","unstructured":"Skucha A, Ebner J, Grebien F. Roles of SETD2 in leukemia\u2014transcription, DNA-damage, and beyond. Int J Mol Sci. 2019;20(5):1029. https:\/\/doi.org\/10.3390\/IJMS20051029","journal-title":"Int J Mol Sci"},{"key":"1831_CR43","doi-asserted-by":"publisher","unstructured":"Alford JS, Lampe JW, Brach D, Chesworth R, Cosmopoulos K, Duncan KW, et al. Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies. ACS Med Chem Lett. 2022;13:1137\u201343. https:\/\/doi.org\/10.1021\/ACSMEDCHEMLETT.2C00167","DOI":"10.1021\/ACSMEDCHEMLETT.2C00167"},{"key":"1831_CR44","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3324\/HAEMATOL.2018.207118","volume":"104","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104:1565. https:\/\/doi.org\/10.3324\/HAEMATOL.2018.207118.","journal-title":"Haematologica"},{"key":"1831_CR45","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1182\/BLOODADVANCES.2023010179","volume":"7","author":"P Fenaux","year":"2023","unstructured":"Fenaux P, Gobbi M, Kropf PL, Issa JPJ, Roboz GJ, Mayer J, et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 2023;7:5027\u201337. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2023010179.","journal-title":"Blood Adv"},{"key":"1831_CR46","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/BLOODADVANCES.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6:2219\u201329. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021006138.","journal-title":"Blood Adv"},{"key":"1831_CR47","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine. 2020;383:2526\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"New England Journal of Medicine"},{"key":"1831_CR48","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/BLOODADVANCES.2020001503","volume":"4","author":"S Choe","year":"2020","unstructured":"Choe S, Wang H, DiNardo CD, Stein EM, de Botton S, Roboz GJ, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4:1894\u2013905. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020001503.","journal-title":"Blood Adv"},{"key":"1831_CR49","doi-asserted-by":"publisher","first-page":"639387","DOI":"10.3389\/fonc.2021.639387","volume":"11","author":"C Cerchione","year":"2021","unstructured":"Cerchione C, Romano A, Daver N, DiNardo C, Jabbour EJ, Konopleva Met al. IDH1\/IDH2 Inhibition in Acute Myeloid Leukemia. Front Oncol. 2021;11:639387. https:\/\/doi.org\/10.3389\/fonc.2021.639387","journal-title":"Front Oncol"},{"key":"1831_CR50","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.6004\/JADPRO.2019.10.5.7","volume":"383","author":"L Merchant","year":"2019","unstructured":"Merchant L, Culos K PDS, Wyatt PDBCOPKH, Ivosidenib:PDCSPH.IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia. J Adv Pract Oncol. 2019;383:2526-2537. https:\/\/doi.org\/10.6004\/JADPRO.2019.10.5.7","journal-title":"J Adv Pract Oncol"},{"key":"1831_CR51","doi-asserted-by":"publisher","unstructured":"Chen X, Xing H, Xie X, Kou L, Li J, Li Y. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis. Clin Epigenetics. 2023;15:1\u201312. https:\/\/doi.org\/10.1186\/s13148-023-01529-2","DOI":"10.1186\/s13148-023-01529-2"},{"key":"1831_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/BLCTT.S177913","volume":"9","author":"JE Meg\u00edas-Vericat","year":"2019","unstructured":"Meg\u00edas-Vericat JE, Ballesta-L\u00f3pez O, Barrag\u00e1n E, Montesinos P. IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer. 2019;9:19. . https:\/\/doi.org\/10.2147\/BLCTT.S177913","journal-title":"Blood Lymphat Cancer"},{"key":"1831_CR53","unstructured":"Study Details | A Study of Gilteritinib Versus Midostaurin in Combination With. Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04027309"},{"key":"1831_CR54","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/HEMATOLOGY.2019000058","volume-title":"Hematology: the American Society of Hematology Education Program [Internet]","author":"CC Smith","year":"2019","unstructured":"Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology Am Soc Hematol Educ Program. 2019;2019(1):539-547. https:\/\/doi.org\/10.1182\/HEMATOLOGY.2019000058"},{"key":"1831_CR55","doi-asserted-by":"publisher","unstructured":"Luger SM, Sun Z, Loghavi S, Lazarus HM, Rowe JM, Tallman MS, et al. Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). Blood. 2019:1309\u20131309. https:\/\/doi.org\/10.1182\/BLOOD-2019-128377","DOI":"10.1182\/BLOOD-2019-128377"},{"key":"1831_CR56","doi-asserted-by":"publisher","unstructured":"Ramsey JM, Kettyle LMJ, Sharpe DJ, Mulgrew NM, Dickson GJ, Bijl JJ, et al. Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia. Stem Cells. 2013;1434\u201345. https:\/\/doi.org\/10.1002\/STEM.1398.","DOI":"10.1002\/STEM.1398"},{"key":"1831_CR57","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1200\/JCO.2013.31.15_SUPPL.7116","volume":"31","author":"SM Luger","year":"2013","unstructured":"Luger SM, O\u2019Connell CL, Klimek V, Cooper MA, Besa EC, Rossetti JM, et al. A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). American Society of Clinical Oncology. 2013;31:7116\u20137116. https:\/\/doi.org\/10.1200\/JCO.2013.31.15_SUPPL.7116.","journal-title":"American Society of Clinical Oncology"},{"key":"1831_CR58","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/HAEMATOL.2017.172411","volume":"103","author":"RF Schlenk","year":"2018","unstructured":"Schlenk RF, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, et al. Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. Haematologica. 2018;103:e25. https:\/\/doi.org\/10.3324\/HAEMATOL.2017.172411.","journal-title":"Haematologica"},{"key":"1831_CR59","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/HAEMATOL.2009.009217","volume":"94","author":"EW Schaefer","year":"2009","unstructured":"Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94:1375. https:\/\/doi.org\/10.3324\/HAEMATOL.2009.009217.","journal-title":"Haematologica"},{"key":"1831_CR60","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.007071","author":"B Scholz","year":"2019","unstructured":"Scholz B, Schulte JS, Hamer S, Himmler K, Pluteanu F, Seidl MD, et al. HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice. Circ Arrhythm Electrophysiol. 2019;12(3):e007071. https:\/\/doi.org\/10.1161\/CIRCEP.118.007071","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1831_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJV335","author":"JF Zeidner","year":"2016","unstructured":"Zeidner JF, Karp JE, Blackford AL, Foster MC, Dees EC, Smith G, et al. Phase I clinical trials in acute myeloid leukemia: 23-year experience from cancer therapy evaluation program of the National Cancer Institute. J Natl Cancer Inst. 2016;108(3). https:\/\/doi.org\/10.1093\/JNCI\/DJV335","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1831_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70023","volume":"4","author":"N Lu","year":"2025","unstructured":"Lu N, Rong G, Han W. Epi-immunotherapy in cancer treatment: mechanisms, clinical progress, and future directions. Cancer Innovation. 2025;4:e70023. https:\/\/doi.org\/10.1002\/cai2.70023","journal-title":"Cancer Innov"},{"key":"1831_CR63","doi-asserted-by":"publisher","unstructured":"Gambacorta V, Gnani D, Vago L, Di Micco R. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Front Cell Dev Biol 2019;7:474143. https:\/\/doi.org\/10.3389\/fcell.2019.00207","DOI":"10.3389\/fcell.2019.00207"},{"key":"1831_CR64","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/2159-8290.CD-25-0587","volume":"15","author":"C Huang","year":"2025","unstructured":"Huang C, Gao Y, Chen J, Hong JH, Jiang Y, Chai KXY, et al. Priming with DNMT inhibitors potentiates PD-1 immunotherapy by triggering viral mimicry in relapsed\/refractory NK\/T-cell lymphoma. Cancer Discov. 2025;15:2450. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0587.","journal-title":"Cancer Discov"},{"key":"1831_CR65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. [Internet]","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280-1288. https:\/\/doi.org\/10.1038\/leu.2013.355"},{"key":"1831_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/MTNA.2014.32","author":"H Sun","year":"2014","unstructured":"Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014;3:e182. https:\/\/doi.org\/10.1038\/MTNA.2014.32","journal-title":"Mol Ther Nucleic Acids [Internet] Mol Ther Nucleic Acids"},{"key":"1831_CR67","doi-asserted-by":"publisher","unstructured":"Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006;103(32):11838\u201343. https:\/\/doi.org\/10.1073\/PNAS.0602615103","DOI":"10.1073\/PNAS.0602615103"},{"key":"1831_CR68","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1080\/10717544.2017.1367976","volume":"24","author":"H Wu","year":"2017","unstructured":"Wu H, Wang M, Dai B, Zhang Y, Yang Y, Li Q, et al. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Delivery. 2017;24:1216\u201329. https:\/\/doi.org\/10.1080\/10717544.2017.1367976","journal-title":"Drug Deliv"},{"key":"1831_CR69","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/S41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374. https:\/\/doi.org\/10.1038\/S41375-018-0180-3.","journal-title":"Leukemia"},{"key":"1831_CR70","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/LEU.2014.128","volume":"28","author":"SJ Busfield","year":"2014","unstructured":"Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28:2213\u201321. https:\/\/doi.org\/10.1038\/LEU.2014.128.","journal-title":"Leukemia"},{"key":"1831_CR71","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","volume":"17","author":"F Li","year":"2018","unstructured":"Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, et al. Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. Mol Cancer Ther. 2018;17:554\u201364. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0742.","journal-title":"Mol Cancer Ther"},{"key":"1831_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1945804","author":"JE Meyer","year":"2021","unstructured":"Meyer JE, Loff S, Dietrich J, Spehr J, Jurado Jim\u00e9nez G, von Bonin M, et al. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. Oncoimmunology. 2021;10(1):1945804. https:\/\/doi.org\/10.1080\/2162402X.2021.1945804","journal-title":"Oncoimmunology"},{"key":"1831_CR73","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536A","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u201341. https:\/\/doi.org\/10.1038\/415536A.","journal-title":"Nature"},{"key":"1831_CR74","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/J.CELL.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286\u201399. https:\/\/doi.org\/10.1016\/J.CELL.2009.05.045.","journal-title":"Cell"},{"key":"1831_CR75","doi-asserted-by":"publisher","unstructured":"Lu N, Rong G, Han W. Epi-Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future Directions. Cancer Innovation. 2025;4:e70023. https:\/\/doi.org\/10.1002\/CAI2.70023","DOI":"10.1002\/CAI2.70023"},{"key":"1831_CR76","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","volume":"56","author":"SZ He","year":"2015","unstructured":"He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, et al. A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia & Lymphoma. 2015;56(5):1406\u20131415. https:\/\/doi.org\/10.3109\/10428194.2014.956316","journal-title":"Leuk Lymphoma"},{"key":"1831_CR77","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/HAEMATOL.2014.113092","volume":"100","author":"EM Lee","year":"2015","unstructured":"Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015;100:914. https:\/\/doi.org\/10.3324\/HAEMATOL.2014.113092.","journal-title":"Haematologica"},{"key":"1831_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0645-z","author":"AS Kubasch","year":"2019","unstructured":"Kubasch AS, Schulze F, Giagounidis A, G\u00f6tze KS, Kr\u00f6nke J, Sockel K, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia 2019;34:1182\u20136. https:\/\/doi.org\/10.1038\/s41375-019-0645-z","journal-title":"Leukemia"},{"key":"1831_CR79","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, Pabst T, H\u00f6pner S, Bacher U, Hinterbrandner M, Banz Y, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature Medicine. 2020;26:1459. https:\/\/doi.org\/10.1038\/s41591-020-0910-8","journal-title":"Nature Medicine"},{"key":"1831_CR80","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, Julie O\u2019Connor NW, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110\u20136. https:\/\/doi.org\/10.1200\/JCO.2005.09.133.","journal-title":"J Clin Oncol"},{"key":"1831_CR81","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369\u201377. https:\/\/doi.org\/10.1200\/JCO.2010.31.4310.","journal-title":"J Clin Oncol"},{"key":"1831_CR82","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Venditti A, Voso MT, Annino L, De Fabritiis P, Alimena G, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34:972\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.64.0060.","journal-title":"J Clin Oncol"},{"key":"1831_CR83","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/BLOODADVANCES.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2:848\u201358. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2018017517.","journal-title":"Blood Adv"},{"key":"1831_CR84","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/BLOODADVANCES.2018020107","volume":"2","author":"YP Jiang","year":"2018","unstructured":"Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2:1738\u201349. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2018020107.","journal-title":"Blood Adv"},{"key":"1831_CR85","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/LEU.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484\u201391. https:\/\/doi.org\/10.1038\/LEU.2015.214","journal-title":"Leuk"},{"key":"1831_CR86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/BLOOD-2014-05-575704","volume":"127","author":"M Al-Hussaini","year":"2016","unstructured":"Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122\u201331. https:\/\/doi.org\/10.1182\/BLOOD-2014-05-575704.","journal-title":"Blood"},{"key":"1831_CR87","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/LEU.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJD, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637\u201347. https:\/\/doi.org\/10.1038\/LEU.2015.52.","journal-title":"Leukemia"},{"key":"1831_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2020-000845","author":"ML Baroni","year":"2020","unstructured":"Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. Journal for ImmunoTherapy of Cancer. 2020;8:e000845. https:\/\/doi.org\/10.1136\/JITC-2020-000845","journal-title":"J Immunother Cancer"},{"key":"1831_CR89","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/MT.2014.164","volume":"23","author":"QS Wang","year":"2015","unstructured":"Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Molecular Therapy. 2015;23:184\u201391. https:\/\/doi.org\/10.1038\/MT.2014.164","journal-title":"Mol Ther"},{"key":"1831_CR90","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","volume":"22","author":"A Mardiros","year":"2015","unstructured":"Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Current Opinion in Hematology. 2015;22:484\u20138. https:\/\/doi.org\/10.1097\/MOH.0000000000000190","journal-title":"Curr Opin Hematol"},{"key":"1831_CR91","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/MT.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122\u20139. https:\/\/doi.org\/10.1038\/MT.2013.154.","journal-title":"Mol Ther"},{"key":"1831_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-017-0553-5","author":"J Wang","year":"2018","unstructured":"Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7. https:\/\/doi.org\/10.1186\/S13045-017-0553-5","journal-title":"J Hematol Oncol"},{"key":"1831_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS18112259","author":"E Laborda","year":"2017","unstructured":"Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, et al. Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017;18:2259. https:\/\/doi.org\/10.3390\/IJMS18112259","journal-title":"Int J Mol Sci"},{"key":"1831_CR94","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/J.YMTHE.2019.12.014","volume":"28","author":"YA Yeung","year":"2020","unstructured":"Yeung YA, Krishnamoorthy V, Dettling D, Sommer C, Poulsen K, Ni I, et al. An Optimized Full-Length FLT3\/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity. Mol Ther. 2020;28:889\u2013900. https:\/\/doi.org\/10.1016\/J.YMTHE.2019.12.014.","journal-title":"Mol Ther"},{"key":"1831_CR95","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/HUM.2020.216","volume":"32","author":"A Stornaiuolo","year":"2021","unstructured":"Stornaiuolo A, Valentinis B, Sirini C, Scavullo C, Asperti C, Zhou D, et al. Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer. Hum Gene Ther. 2021;32:744\u201360. https:\/\/doi.org\/10.1089\/HUM.2020.216.","journal-title":"Hum Gene Ther"},{"key":"1831_CR96","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1089\/hum.2017.241","volume":"29","author":"S Li","year":"2018","unstructured":"Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, et al. CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype. Human Gene Therapy. 2018;29:626\u201339. https:\/\/doi.org\/10.1089\/hum.2017.241","journal-title":"Hum Gene Ther"},{"key":"1831_CR97","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193:216\u201330. https:\/\/doi.org\/10.1111\/bjh.17186","journal-title":"Br J Haematol John Wiley Sons Inc"},{"key":"1831_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-021-01083-5","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;193:216-230. https:\/\/doi.org\/10.1186\/S13045-021-01083-5","journal-title":"J Hematol Oncol"},{"key":"1831_CR99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033.","journal-title":"Blood"},{"key":"1831_CR100","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/BLOODADVANCES.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2:224\u201334. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2017014175.","journal-title":"Blood Adv"},{"key":"1831_CR101","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","volume":"17","author":"P Chevallier","year":"2021","unstructured":"Chevallier P, Saiagh S, Dehame V, Guillaume T, Peterlin P, Bercegeay S, et al. A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.Human Vaccines & Immunotherapeutics. 2021;17(10):3511\u20133514. https:\/\/doi.org\/10.1080\/21645515.2021.1943991","journal-title":"Hum Vaccin Immunother"},{"key":"1831_CR102","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","volume":"56","author":"SZ He","year":"2015","unstructured":"He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, et al. A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia & Lymphoma. 2015;56:1406\u201315. https:\/\/doi.org\/10.3109\/10428194.2014.956316","journal-title":"Leuk Lymphoma"},{"key":"1831_CR103","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/HAEMATOL.2014.113092","volume":"100","author":"EM Lee","year":"2015","unstructured":"Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015;100:914. https:\/\/doi.org\/10.3324\/HAEMATOL.2014.113092.","journal-title":"Haematologica"},{"key":"1831_CR104","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3324\/HAEMATOL.2022.281563","volume":"108","author":"T Pabst","year":"2023","unstructured":"Pabst T, Vey N, Ad\u00e8s L, Bacher U, Bargetzi M, Fung S, et al. Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. Haematologica. 2023;108:1793\u2013802. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.281563","journal-title":"Haematol [Internet] Haematol"},{"key":"1831_CR105","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4161\/MABS.1.5.9288","volume-title":"Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs [Internet]","author":"MK Sutherland","year":"2009","unstructured":"Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, et al. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2009;1(5):481\u2013490. https:\/\/doi.org\/10.4161\/MABS.1.5.9288"},{"key":"1831_CR106","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369\u201377. https:\/\/doi.org\/10.1200\/JCO.2010.31.4310.","journal-title":"J Clin Oncol"},{"key":"1831_CR107","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/AJH.23795","volume":"89","author":"G Borthakur","year":"2014","unstructured":"Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O\u2019Brien S, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89:964\u20138. https:\/\/doi.org\/10.1002\/AJH.23795","journal-title":"Am J Hematol [Internet] Am J Hematol"},{"key":"1831_CR108","doi-asserted-by":"publisher","first-page":"TPS7563","DOI":"10.1200\/JCO.2020.38.15_SUPPL.TPS7563","volume":"38","author":"NG Daver","year":"2020","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, et al. A phase I\/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed\/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. J Clin Oncol. 2020;38:TPS7563\u2013TPS7563. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.TPS7563.","journal-title":"J Clin Oncol"},{"key":"1831_CR109","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1182\/BLOOD.V126.23.330.330","volume-title":"SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML. Blood [Internet]","author":"MSK Sutherland","year":"2015","unstructured":"Sutherland MSK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, et al. SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML. Blood. 2015;126:330-330. https:\/\/doi.org\/10.1182\/BLOOD.V126.23.330.330"},{"key":"1831_CR110","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3\/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13:1549\u201357. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0956.","journal-title":"Mol Cancer Ther"},{"key":"1831_CR111","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","volume":"59","author":"KD Cummins","year":"2018","unstructured":"Cummins KD, Gill S. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. Leukemia & Lymphoma. 2018;59:1539\u201353. https:\/\/doi.org\/10.1080\/10428194.2017.1375107","journal-title":"Leuk Lymphoma"},{"key":"1831_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14051241","author":"P Vishwasrao","year":"2022","unstructured":"Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Emerging CAR T cell strategies for the treatment of AML. Cancers (Basel). 2022;14:1241. https:\/\/doi.org\/10.3390\/CANCERS14051241","journal-title":"Cancers (Basel)"},{"key":"1831_CR113","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang P, Li Z, He Y, Gan W, Jiang H. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27:3549\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4543.","journal-title":"Clin Cancer Res"},{"key":"1831_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES10102441","author":"MG Pedersen","year":"2022","unstructured":"Pedersen MG, M\u00f8ller BK, Bak RO. Recent advances in the development of anti-FLT3 CAR T-cell therapies for treatment of AML. Biomedicines. 2022;10:2441. https:\/\/doi.org\/10.3390\/BIOMEDICINES10102441","journal-title":"Biomedicines"},{"key":"1831_CR115","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/BLOOD.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135:713\u201323. https:\/\/doi.org\/10.1182\/BLOOD.2019002779.","journal-title":"Blood"},{"key":"1831_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-020-00996-X","author":"J Xu","year":"2020","unstructured":"Xu J, Niu T. Natural killer cell-based immunotherapy for acute myeloid leukemia. J Hematol Oncol. 2020;13:167. https:\/\/doi.org\/10.1186\/S13045-020-00996-X","journal-title":"J Hematol Oncol"},{"key":"1831_CR117","doi-asserted-by":"publisher","first-page":"1265299","DOI":"10.3389\/FIMMU.2023.1265299","volume":"14","author":"H Cao","year":"2023","unstructured":"Cao H, Wu T, Zhou X, Xie S, Sun H, Sun Y, et al. Progress of research on PD-1\/PD-L1 in leukemia. Front Immunol. 2023;14:1265299. https:\/\/doi.org\/10.3389\/FIMMU.2023.1265299","journal-title":"Front Immunol Front Media SA"},{"key":"1831_CR118","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia & Lymphoma. 2018;59:790. https:\/\/doi.org\/10.1080\/10428194.2017.1344905","journal-title":"Leuk Lymphoma"},{"key":"1831_CR119","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/BLOODADVANCES.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2:224. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2017014175.","journal-title":"Blood Adv"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01831-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01831-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01831-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:57Z","timestamp":1790680857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01831-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1831"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01831-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"99"}}